Perigon Wealth Management
CRSP icon

Perigon Wealth Management’s CRISPR Therapeutics CRSP Stock Holding History

Perigon Wealth Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.36M Buy
24,643
+1,667
+7% +$90K 0.02% 503
2026
Q2 		$1.25M Buy
22,976
+2,910
+15% +$153K 0.02% 517
2026
Q1 		$955K Buy
20,066
+1,007
+5% +$53.1K 0.02% 553
2025
Q4 		$999K Buy
19,059
+367
+2% +$22K 0.02% 550
2025
Q3 		$1.21M Buy
18,692
+380
+2% +$21.8K 0.02% 456
2025
Q2 		$891K Buy
18,312
+1,538
+9% +$59.5K 0.02% 502
2025
Q1 		$571K Buy
16,774
+17
+0.1% +$721 0.01% 601
2024
Q4 		$675K Buy
16,757
+1,717
+11% +$81.1K 0.02% 556
2024
Q3 		$707K Buy
15,040
+388
+3% +$19.7K 0.02% 518
2024
Q2 		$791K Sell
14,652
-89
-0.6% -$5.15K 0.02% 427
2024
Q1 		$1M Sell
14,741
-177
-1% -$12.7K 0.03% 370
2023
Q4 		$934K Buy
14,918
+609
+4% +$33.7K 0.03% 355
2023
Q3 		$649K Buy
14,309
+2,925
+26% +$151K 0.03% 391
2023
Q2 		$639K Sell
11,384
-206
-2% -$11.7K 0.03% 395
2023
Q1 		$524K Sell
11,590
-358
-3% -$17.4K 0.03% 385
2022
Q4 		$486K Sell
11,948
-123
-1% -$6.52K 0.03% 394
2022
Q3 		$789K Buy
12,071
+186
+2% +$13.5K 0.07% 241
2022
Q2 		$722K Buy
11,885
+1,356
+13% +$79.7K 0.06% 261
2022
Q1 		$661K Buy
10,529
+1,866
+22% +$117K 0.05% 298
2021
Q4 		$656K Buy
8,663
+1,397
+19% +$122K 0.05% 284
2021
Q3 		$813K Buy
7,266
+450
+7% +$56.5K 0.07% 226
2021
Q2 		$1.1M Buy
6,816
+378
+6% +$46K 0.1% 179
2021
Q1 		$784K Buy
6,438
+830
+15% +$125K 0.08% 211
2020
Q4 		$859K Buy
5,608
+538
+11% +$63.6K 0.1% 161
2020
Q3 		$424K Buy
5,070
+143
+3% +$12.7K 0.06% 247
2020
Q2 		$362K Sell
4,927
-1,425
-22% -$83.3K 0.06% 238
2020
Q1 		$291K Buy
6,352
+1,721
+37% +$88.9K 0.05% 239
2019
Q4 		$278K Buy
+4,631
New +$253K 0.06% 209

Other funds holding CRSP

GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Perigon Wealth Management's CRSP Position: Q3 2026 in Review

Perigon Wealth Management increased its CRISPR Therapeutics (CRSP) stake by 7.3% in Q3 2026, buying an estimated $90K and bringing the position to 24,643 shares worth $1.36M. The position accounts for 0.02% of the portfolio, ranked #503.

Perigon Wealth Management first reported a position in CRSP in Q4 2019 and has held it in 28 quarters since. 286 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Perigon Wealth Management held 24,643 shares of CRISPR Therapeutics worth $1.36M as of Q3 2026.
  • Perigon Wealth Management bought 1,667 CRISPR Therapeutics shares in Q3 2026, an estimated $90K.
  • CRISPR Therapeutics made up 0.02% of Perigon Wealth Management's portfolio in Q3 2026, its #503 holding.
  • Perigon Wealth Management first reported a position in CRISPR Therapeutics in Q4 2019 and has held it in 28 quarters since.
  • 286 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Perigon Wealth Management's 13F filing for Q3 2026, filed 22 Oct 2026.